

Carter Van Waes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6988654/publications.pdf>

Version: 2024-02-01

76
papers

5,076
citations

87888

38
h-index

98798

67
g-index

77
all docs

77
docs citations

77
times ranked

8198
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibiting WEE1 and IKK-RELA Crosstalk Overcomes TNF \pm Resistance in Head and Neck Cancers. <i>Molecular Cancer Research</i> , 2022, 20, 867-882.	3.4	5
2	Abstract 2988: Proteasomal deubiquitinases represent an attractive therapeutic target in head and neck squamous cell carcinomas (HNSCC). <i>Cancer Research</i> , 2022, 82, 2988-2988.	0.9	1
3	Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas. <i>Scientific Reports</i> , 2021, 11, 6392.	3.3	1
4	The Proteomic Landscape of Growth Factor Signaling Networks Associated with <i>FAT1</i> Mutations in Head and Neck Cancers. <i>Cancer Research</i> , 2021, 81, 4402-4416.	0.9	16
5	Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1295-1305.	0.8	6
6	Comprehensive multiomic characterization of human papillomavirus-driven recurrent respiratory papillomatosis reveals distinct molecular subtypes. <i>Communications Biology</i> , 2021, 4, 1416.	4.4	10
7	A comprehensive, multidisciplinary, precision medicine approach to discover effective therapy for an undiagnosed, progressive, fibroinflammatory disease. <i>Translational Research</i> , 2020, 215, 31-40.	5.0	0
8	Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 679-689.	7.0	49
9	Regulation of NF κ B Signalling by Ubiquitination: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma?. <i>Cancers</i> , 2020, 12, 2877.	3.7	20
10	ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer. <i>Oncot Immunology</i> , 2020, 9, 1710398.	4.6	30
11	Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. <i>ELife</i> , 2020, 9, .	6.0	32
12	Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition. <i>Oncot Immunology</i> , 2019, 8, e1638207.	4.6	39
13	Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. <i>Oral Oncology</i> , 2019, 95, 127-135.	1.5	103
14	Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV \pm and HPV+ Head and Neck Cancers to TNF \pm , TRAIL, and Radiation Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 6463-6474.	7.0	28
15	Head and Neck Cancers Promote an Inflammatory Transcriptome through Coactivation of Classic and Alternative NF- κ B Pathways. <i>Cancer Immunology Research</i> , 2019, 7, 1760-1774.	3.4	17
16	Integrated Genomic and Functional microRNA Analysis Identifies miR-30-5p as a Tumor Suppressor and Potential Therapeutic Nanomedicine in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2860-2873.	7.0	68
17	Lymphotoxin β receptor β signaling induces alternative RELB/NF κ B2 activation to promote metastatic gene expression and cell migration in head and neck cancer. <i>Molecular Carcinogenesis</i> , 2019, 58, 411-425.	2.7	16
18	Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. <i>JCI Insight</i> , 2019, 4, .	5.0	168

#	ARTICLE	IF	CITATIONS
19	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
20	Nanocomplex-based TP53 gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanisms. <i>Oncolmmunology</i> , 2018, 7, e1404216.	4.6	26
21	PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation. <i>Oncolmmunology</i> , 2018, 7, e1395996.	4.6	90
22	Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers. <i>Cell Reports</i> , 2018, 25, 1332-1345.e5.	6.4	66
23	Targeting Notch1 and IKK β Enhanced NF- κ B Activation in CD133+ Skin Cancer Stem Cells. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2034-2048.	4.1	22
24	WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1488359.	4.6	41
25	Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. <i>Oncolmmunology</i> , 2018, 7, e1471440.	4.6	43
26	Attenuated TRAF3 Fosters Activation of Alternative NF- κ B and Reduced Expression of Antiviral Interferon, TP53, and RB to Promote HPV-Positive Head and Neck Cancers. <i>Cancer Research</i> , 2018, 78, 4613-4626.	0.9	27
27	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , 2017, 31, 820-832.e3.	16.8	433
28	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K β . <i>Cancer Research</i> , 2017, 77, 2607-2619.	0.9	165
29	Genetic alterations in TRAF3 and CYLD that regulate nuclear factor κ B and interferon signaling define head and neck cancer subsets harboring human papillomavirus. <i>Cancer</i> , 2017, 123, 1695-1698.	4.1	5
30	Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways. <i>Clinical Cancer Research</i> , 2017, 23, 1379-1387.	7.0	117
31	Genomics and advances towards precision medicine for head and neck squamous cell carcinoma. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 310-319.	1.5	12
32	Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2017, 5, 1141-1151.	3.4	160
33	Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. <i>Oncotarget</i> , 2017, 8, 55804-55820.	1.8	75
34	Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer. <i>Case Reports in Otolaryngology</i> , 2016, 2016, 1-5.	0.2	5
35	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. <i>Oral Oncology</i> , 2016, 58, 59-70.	1.5	115
36	Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers. <i>Cancer Immunology Research</i> , 2016, 4, 611-620.	3.4	73

#	ARTICLE	IF	CITATIONS
37	SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes <i>FADD</i> and <i>BIRC2</i> . <i>Cancer Research</i> , 2016, 76, 5442-5454.	0.9	59
38	Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 1061-1071.	3.4	114
39	Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. <i>Head and Neck</i> , 2016, 38, 1176-1186.	2.0	17
40	Clonally expanded CD4 ⁺ T cells can produce infectious HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1883-1888.	7.1	302
41	Conditional deletion of nonmuscle myosin II-A in mouse tongue epithelium results in squamous cell carcinoma. <i>Scientific Reports</i> , 2015, 5, 14068.	3.3	45
42	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. <i>Cancers</i> , 2015, 7, 2397-2414.	3.7	61
43	MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 3946-3956.	7.0	60
44	<i>CCR</i> 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 942-943.	7.0	7
45	Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384. <i>Clinical Cancer Research</i> , 2015, 21, 2792-2801.	7.0	62
46	Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer. <i>Cell and Bioscience</i> , 2015, 5, 53.	4.8	29
47	Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3227-3234.	1.6	125
48	mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. <i>Oncotarget</i> , 2015, 6, 36400-36417.	1.8	43
49	CK2 Phosphorylates and Inhibits TAp73 Tumor Suppressor Function to Promote Expression of Cancer Stem Cell Genes and Phenotype in Head and Neck Cancer. <i>Neoplasia</i> , 2014, 16, 789-800.	5.3	27
50	Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF- κ B signaling. <i>Oral Oncology</i> , 2014, 50, 930-941.	1.5	46
51	PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3808-3819.	7.0	73
52	Signaling Networks of Activated Oncogenic and Altered Tumor Suppressor Genes in Head and Neck Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2013, Suppl 7, 4.	0.3	5
53	Targeting NF- κ B in Mouse Models of Lung Adenocarcinoma: Figure 1.. <i>Cancer Discovery</i> , 2011, 1, 200-202.	9.4	4
54	Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Locally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 447-454.	0.8	33

#	ARTICLE	IF	CITATIONS
55	Nuclear Factor- κ B in Development, Prevention, and Therapy of Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 1076-1082.	7.0	296
56	Inhibitor- κ B Kinase in Tumor Promotion and Suppression During Progression of Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2007, 13, 4956-4959.	7.0	27
57	Role of activated nuclear factor- κ B in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2007, 29, 959-971.	2.0	99
58	Inhibition of nuclear factor- κ B and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1400-1412.	0.8	113
59	Head and Neck Squamous Cell Carcinoma in Patients With Fanconi Anemia. <i>JAMA Otolaryngology</i> , 2005, 131, 640.	1.2	7
60	Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF- κ B and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. <i>International Journal of Cancer</i> , 2002, 99, 538-548.	5.1	217
61	Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1 β , EGF and TGF- β 1 through NF- κ B dependent and independent mechanisms. <i>International Journal of Cancer</i> , 2001, 94, 637-644.	5.1	46
62	Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?. <i>FASEB Journal</i> , 2000, 14, 1499-1507.	0.5	55
63	IL-12- and IL-2-induced tumor regression in a new murine model of oral squamous-cell carcinoma is promoted by expression of the CD80 co-stimulatory molecule and interferon- γ . , 2000, 86, 368-374.		37
64	Cisplatin and radiation sensitivity in human head and neck squamous carcinomas are independently modulated by glutathione and transcription factor NF- κ B. <i>Head and Neck</i> , 2000, 22, 748-759.	2.0	81
65	Growth Regulated Oncogene- β expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC Receptor-2 dependent mechanism. <i>Oncogene</i> , 2000, 19, 3477-3486.	5.9	157
66	Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?. <i>FASEB Journal</i> , 2000, 14, 1499-1507.	0.5	70
67	Constitutive activation of transcription factors NF- κ B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. , 1999, 26, 119-129.		197
68	Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. , 1999, 82, 377-384.		36
69	Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. , 1999, 82, 377.		1
70	Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma. <i>International Journal of Cancer</i> , 1999, 82, 377-384.	5.1	2
71	The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1 α , IL-6, GM-CSF, and KC. <i>Clinical and Experimental Metastasis</i> , 1998, 16, 655-664.	3.3	60
72	Intravenous delivery of 5-iododeoxyuridine during hyperfractionated radiotherapy for locally advanced head and neck cancers: Results of a pilot study. <i>Laryngoscope</i> , 1998, 108, 1090-1094.	2.0	9

#	ARTICLE	IF	CITATIONS
73	Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction. <i>Clinical and Experimental Metastasis</i> , 1997, 15, 527-537.	3.3	41
74	Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. <i>Journal of Cellular Biochemistry</i> , 1997, 67, 90-100.	2.6	42
75	Cell adhesion and regulatory molecules involved in tumor formation, hemostasis, and wound healing. <i>Head and Neck</i> , 1995, 17, 140-147.	2.0	42
76	Squamous-cell carcinoma. , 0, , 686-692.		0